Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Common Equity: 2022-2024

Historic Common Equity for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $229.0 million.

  • Stoke Therapeutics' Common Equity rose 32.74% to $308.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.1 million, marking a year-over-year increase of 32.74%. This contributed to the annual value of $229.0 million for FY2024, which is 43.53% up from last year.
  • Stoke Therapeutics' Common Equity amounted to $229.0 million in FY2024, which was up 43.53% from $159.6 million recorded in FY2023.
  • Stoke Therapeutics' 5-year Common Equity high stood at $229.0 million for FY2024, and its period low was $159.6 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was $184.8 million (2022), whereas its average is $191.1 million.
  • Per our database at Business Quant, Stoke Therapeutics' Common Equity fell by 13.68% in 2023 and then spiked by 43.53% in 2024.
  • Over the past 3 years, Stoke Therapeutics' Common Equity (Yearly) stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then skyrocketed by 43.53% to $229.0 million in 2024.